A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) – AGMT_CMML-1. 23. April 2019 1. Mai 2018 Share EmailTwitterFacebookGoogle +PinterestTumblrLinkedinVkontakte
